The landscape of oncology drug development is undergoing a profound transformation, increasingly centered on precision immunotherapies where biomarker-defined patient populations…
Read More
Emerging therapies bring hope for frail HNSCC patients unfit for standard treatment – Pharmaceutical Technology
The global burden of head and neck squamous cell carcinoma (HNSCC) is on an upward trajectory, with an estimated increase…
Read More
Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D
Pharmaceutical research and development (R&D) stands at a pivotal inflection point, characterized by a dynamic shift away from the traditional…
Read More
Biocytogen and Sihuan Pharmaceutical Forge Strategic Alliance to Accelerate Advanced Therapies, Including Novel Weight Loss Treatments
The pharmaceutical landscape is poised for significant advancement as Biocytogen, a leader in antibody-based drug discovery, and Sihuan Pharmaceutical, a…
Read More
Eli Lilly Ascends to Pharmaceutical Revenue Zenith with Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced
Indianapolis, IN – Eli Lilly and Company, a venerable pharmaceutical giant, has officially seized the top position in global pharmaceutical…
Read More
HNSCC market is expected to reach to $4.5bn across 8MM by 2034 – Pharmaceutical Technology
The global market for head and neck squamous cell carcinoma (HNSCC) therapeutics is poised for significant expansion, with projections indicating…
Read More
Teva Pharmaceutical Secures FDA Approval for Ponlimsi Biosimilar to Prolia, Advances Xolair Biosimilar Applications in US and EU
Teva Pharmaceutical has announced a significant milestone in its biosimilar portfolio with the U.S. Food and Drug Administration (FDA) granting…
Read More
Moving beyond the binary: how the convergence of small and large molecules is reshaping pharmaceutical R&D
Pharmaceutical research and development stands at a pivotal juncture, grappling with a paradoxical shift in drug modality approvals that signals…
Read More
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Bolster Psychiatric and Neurological Pipeline
TOKYO, JAPAN & BOSTON, USA – March 30, 2026 – Otsuka Pharmaceutical Co., Ltd. announced today that its subsidiary, Otsuka…
Read More
Corcept’s first-in-class ovarian cancer drug gains FDA approval – Pharmaceutical Technology
Corcept Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for its selective…
Read MoreYOU MAY HAVE MISSED
